Mina Bissell Phones & Addresses
-
854 Euclid Ave, Berkeley, CA 94708 (510) 527-5486
-
Eugene, OR
-
Boston, MA
-
Inverness, CA
-
Alameda, CA
Emails
Publications
Wikipedia References
Mina Bissell
Work:
Position:
Biologist
Education:
Specialty:
Leader • Director
Academic degree:Bachelor's Degree • PHD
Skills & Activities:
Achieved status:
Iranian emigrant
Award:Highest honors
Skill:Scientific
Mina Bissell
Isbn (Books And Publications)
Gene Expression and Regulation: The Legacy of Luigi Gorini
View page
Author
Mina Bissell
ISBN #
0444809937
Us Patents
Human Azu-1 Gene, Variants Thereof And Expressed Gene Products
View pageUS Patent:
6753154, Jun 22, 2004
Filed:
Jun 25, 1999
Appl. No.:
09/344624
Inventors:
Huei-Mei Chen - Richmond CA
Mina Bissell - Berkeley CA
Mina Bissell - Berkeley CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33574
US Classification:
435 723, 435 4, 435 6, 435 721, 435 84, 435 85, 435 89, 435 911, 435 912, 436 63, 436 64, 436501, 424 91, 424 92, 4241301, 4241381, 530300, 530350, 530386, 5303871, 5303879, 5303881, 53038815, 5303891, 5303897
Abstract:
A human AZU-1 gene, mutants, variants and fragments thereof. Protein products encoded by the AZU-1 gene and homologs encoded by the variants of AZU-1 gene acting as tumor suppressors or markers of malignancy progression and tumorigenicity reversion. Identification, isolation and characterization of AZU-1 and AZU-2 genes localized to a tumor suppressive locus at chromosome 10q26, highly expressed in nonmalignant and premalignant cells derived from a human breast tumor progression model. A recombinant full length protein sequences encoded by the AZU-1 gene and nucleotide sequences of AZU-1 and AZU-2 genes and variant and fragments thereof. Monoclonal or polyclonal antibodies specific to AZU-1, AZU-2 encoded protein and to AZU-1, or AZU-2 encoded protein homologs.
Design Of Novel Assays Based On The Newly Found Role Of Dystroglycan And Alpha-Dystroglycan Proteolysis In Tumor Cell Growth
View pageUS Patent:
6982151, Jan 3, 2006
Filed:
Aug 31, 2000
Appl. No.:
09/652493
Inventors:
Mina J. Bissell - Berkeley CA, US
John L. Muschler - Berkeley CA, US
John L. Muschler - Berkeley CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/577
US Classification:
435 723, 435 78, 436501, 436518
Abstract:
The invention provides method for assessing tumorigenicity of mammalian cells by assaying the proteolytic fragments of 120-130 kD alpha-dystroglycan in medium surrounding mammalian cells.
Method Of Increasing Radiation Sensitivity By Inhibition Of Beta One Integrin
View pageUS Patent:
7618627, Nov 17, 2009
Filed:
Jun 2, 2005
Appl. No.:
11/628476
Inventors:
Catherine Park - San Francisco CA, US
Mina J. Bissell - Berkeley CA, US
Mina J. Bissell - Berkeley CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395
C07K 16/00
C07K 16/00
US Classification:
4241301, 5303871
Abstract:
A method for increasing or monitoring apoptosis in tumor cells by the co-administration of ionizing radiation and an anti-integrin antibody. Increasing apoptosis reduces tumor growth in vivo and in a cell culture model. The antibody is directed against the beta-1 integrin subunit and is inhibitory of beta-1 integrin signaling. Other molecules having an inhibitory effect on beta-1 integrin, either in signaling or in binding to its cognate extracellular receptors may also be used. The present method is particularly of interest in treatment of tumor cells associated with breast cancer, wherein radiation is currently used alone. The present method further contemplates a monoclonal antibody suitable for human administration that may further comprise a radioisotope attached thereto.
Drug Screens Based On The Newly Found Role Of Dystroglycan Proteolysis And Restoration Of Dystroglycan Function Thereof
View pageUS Patent:
7666850, Feb 23, 2010
Filed:
Jun 9, 2005
Appl. No.:
11/150406
Inventors:
Mina J. Bissell - Berkeley CA, US
John L. Muschler - Albany CA, US
John L. Muschler - Albany CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 48/00
G01N 33/536
G01N 33/536
US Classification:
514 44, 435 723
Abstract:
The present invention provides methods and compositions for the diagnosis and treatment of cells lacking normal growth arresting characteristic. The present invention demonstrates that many tumor cells lack normal cell surface α-dystroglycan and thereby lack dystroglycan function. Dystroglycan can be lost from the cell surface by proteolytic shedding of a fragment of α-dystroglycan into the surrounding medium. Upon restoration of dystroglycan function and over-expression of the dystroglycan gene, the once tumorigenic cells revert to non-tumorigenic cells which polarize and arrest cell growth in the presence of basement membrane proteins, demonstrating that dystroglycan functions as a tumor marker and suppressor.
Method Of Increasing Radiation Sensitivity By Inhibition Of Beta One Integrin
View pageUS Patent:
8246952, Aug 21, 2012
Filed:
Oct 7, 2009
Appl. No.:
12/575411
Inventors:
Catherine Park - San Francisco CA, US
Mina J. Bissell - Berkeley CA, US
Mina J. Bissell - Berkeley CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
A method for increasing or monitoring apoptosis in tumor cells by the co-administration of ionizing radiation and an anti-integrin antibody. Increasing apoptosis reduces tumor growth in vivo and in a cell culture model. The antibody is directed against the beta-1 integrin subunit and is inhibitory of beta-1 integrin signaling. Other molecules having an inhibitory effect on beta-1 integrin, either in signaling or in binding to its cognate extracellular receptors may also be used. The present method is particularly of interest in treatment of tumor cells associated with breast cancer, wherein radiation is currently used alone. The present method further contemplates a monoclonal antibody suitable for human administration that may further comprise a radioisotope attached thereto.
Identification Of Rac1B As A Marker And Mediator Of Metalloproteinase-Induced Malignancy
View pageUS Patent:
20090191543, Jul 30, 2009
Filed:
May 26, 2006
Appl. No.:
11/915726
Inventors:
Derek C. Radisky - Jacksonville FL, US
Celeste M. Nelson - Princeton NJ, US
Mina J. Bissell - Berkeley CA, US
Celeste M. Nelson - Princeton NJ, US
Mina J. Bissell - Berkeley CA, US
Assignee:
THEREGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C12Q 1/08
C12N 5/02
G01N 33/574
C07H 21/04
C12N 5/08
C12N 5/02
G01N 33/574
C07H 21/04
C12N 5/08
US Classification:
435 6, 435375, 435366, 435 723, 536 231
Abstract:
The present invention provides compositions and methods for detecting MMP-induced malignancies by detecting Rac1b expression. The invention further provides compositions and in vitro and in vivo methods for inhibiting MMP-induced malignant transformation by modulating Rac1b expression and/or function.
Targeting Tnf-Alpha Converting Enzyme(Tace)- Dependent Growth Factor Shedding In Cancer Therapy
View pageUS Patent:
20090274626, Nov 5, 2009
Filed:
Jan 29, 2008
Appl. No.:
12/022049
Inventors:
Paraic A. Kenny - Templemore, IE
Mina J. Bissell - Berkeley CA, US
Mina J. Bissell - Berkeley CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 49/00
A61K 31/7088
A61K 39/395
A61K 38/00
A61K 31/195
A61K 31/517
A61K 31/5377
A61K 31/506
A61K 33/24
A61K 31/337
A61K 31/7088
A61K 39/395
A61K 38/00
A61K 31/195
A61K 31/517
A61K 31/5377
A61K 31/506
A61K 33/24
A61K 31/337
US Classification:
424 92, 514 44 A, 4241301, 514 44 R, 514 2, 514563, 514561, 5142661, 5142664, 5142345, 51426624, 51425218, 424649, 4241411, 514449
Abstract:
The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.
Rhamm, A Co-Receptor And Its Interactions With Other Receptors In Cancer Cell Motility And The Identification Of Cancer Prognitor Cell Populations
View pageUS Patent:
20100062000, Mar 11, 2010
Filed:
May 21, 2009
Appl. No.:
12/470453
Inventors:
Eva A. Turley - London, CA
Mina J. Bissell - Berkeley CA, US
Francoise Winnik - Westmount, CA
Mina J. Bissell - Berkeley CA, US
Francoise Winnik - Westmount, CA
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 39/395
C12Q 1/04
G01N 33/574
C12N 5/00
A61K 38/02
A61K 31/7052
C12Q 1/02
C12Q 1/68
A61P 35/00
C12Q 1/04
G01N 33/574
C12N 5/00
A61K 38/02
A61K 31/7052
C12Q 1/02
C12Q 1/68
A61P 35/00
US Classification:
4241721, 435 34, 435 723, 435375, 514 2, 514 44 A, 435 29, 435 6
Abstract:
CD44 is an integral hyaluronan receptor that can either promote or inhibit motogenic signaling in tumor cells. Rhamm is a non-integral cell surface (CD168) and intracellular hyaluronan binding protein that promotes cell motility in vitro and whose expression is strongly upregulated in aggressive tumors. The present invention describes compositions and methods for the prognosis and diagnosis of cancer by the detection of CD44/Rhamm complexes. The use of labeled Rhamm-binding agents in culture and in vivo to identify tumorigenic progenitor cells that exhibit an aggressive phenotype characterized by high Rhamm and CD44 expression is further described. Specific methods include using hyaluronan to target imaging or therapeutic agents to these progenitor tumor subsets in breast and likely other cancers.